ICU Medical, Inc. (NASDAQ:ICUI) COO Christian B. Voigtlander Sells 5,556 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) COO Christian B. Voigtlander sold 5,556 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $138.65, for a total value of $770,339.40. Following the completion of the transaction, the chief operating officer now owns 2,389 shares in the company, valued at approximately $331,234.85. The trade was a 69.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

ICU Medical Stock Up 3.4%

Shares of NASDAQ:ICUI opened at $140.54 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The stock has a market cap of $3.46 billion, a P/E ratio of -30.75 and a beta of 0.87. ICU Medical, Inc. has a 1-year low of $100.91 and a 1-year high of $196.26. The firm has a fifty day moving average price of $140.80 and a 200 day moving average price of $154.33.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.49. The firm had revenue of $599.49 million for the quarter, compared to analyst estimates of $574.15 million. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the company posted $0.96 earnings per share. Sell-side analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analyst Ratings Changes

ICUI has been the subject of a number of research analyst reports. Raymond James lowered their price target on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a report on Friday, May 9th. KeyCorp reduced their price objective on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Finally, StockNews.com cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 10th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $192.67.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Barclays PLC lifted its holdings in shares of ICU Medical by 15.6% during the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after purchasing an additional 8,010 shares during the period. Principal Financial Group Inc. increased its stake in ICU Medical by 24.6% in the 3rd quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after buying an additional 25,031 shares during the period. Vanguard Group Inc. raised its position in ICU Medical by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock worth $416,176,000 after buying an additional 17,805 shares during the last quarter. Jennison Associates LLC acquired a new stake in shares of ICU Medical in the 4th quarter worth $556,000. Finally, Franklin Resources Inc. boosted its holdings in shares of ICU Medical by 99.3% in the third quarter. Franklin Resources Inc. now owns 11,708 shares of the medical instruments supplier’s stock valued at $2,111,000 after acquiring an additional 5,834 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.